This opportunity is no longer accepting applications.
grant PAR-22-209

CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)

This grant opportunity is for developing early-stage therapeutics to counteract health problems from toxic chemical exposure, such as in terrorist attacks or industrial accidents. It covers chemical warfare agents, toxic industrial chemicals, pesticides, and certain pharmaceuticals. The grant involves two phases: the UG3 phase, which focuses on validating therapeutic targets and characterizing…

This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released …

Funding Source

Agency: National Institutes of Health
Program: SBIR

Awards & funding

Award Ceiling: $350,000
Award Amount: $350,000

Dates

Opportunity Released: July 6, 2022
Open for Submission: July 6, 2022
Submission Deadline: October 17, 2024
Application Window Closes: October 17, 2024

Documents

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.